Cystic Fibrosis, Fibrosis
Conditions
Keywords
Dornase, Cystic Fibrosis, Fibrosis, Lung Diseases, Pancreatic Diseases, Digestive System Diseases, Respiratory Tract Diseases, Pathologic Processes, Genetic Diseases, Inborn, Tigerase®, DNase
Brief summary
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® compared Pulmozyme® in patients with Cystic Fibrosis
Detailed description
Cystic fibrosis (CF) is a common hereditary disease with an autosomal recessive type of inheritance, characterized by systemic damage to the exocrine glands, mainly the bronchopulmonary and gastrointestinal systems. CF is usually characterized by a severe course and poor prognosis. The severity of the disease and the life expectancy of the patient with CF is determined primarily by the state of the bronchopulmonary system; more than 90% of patients die from lung diseases. CF Pulmonary damage develops as a result of a gene mutation - cystic fibrosis transmembrane regulator of ion conductivity Na and Cl (CFTR-cystic fibrosis transmembrane regulator). The main function of CFTR is to regulate the transport of sodium and chlorine across the cell membrane and is part of the cAMP-dependent chlorine channel. CFTR-protein dysfunction in the bronchial tree epithelial cells leads to a blockage of the chlorine ions transport and an increase in the sodium ions absorption, and impaired fluid secretion through the epithelial cells apical membrane. Dornase alpha, a human recombinant deoxyribonuclease 1 (rhDNase, rhDNase) hydrolyzes extracellular DNA (viscous polyanion) that enters the sputum from destroyed neutrophils, thereby reducing the adhesion and viscosity of sputum. In CF patients dornase alpha is used as symptomatic therapy in combination with standard therapy in patients with a forced vital capacity (FVC) index of at least 40% of the proper value.
Interventions
BIOLOGICALTigerase®
2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
BIOLOGICALPulmozyme®
2.5 mL (2.5 mg) dornase alfa nebulized once daily for 168 (+/-7) days
Sponsors
AO GENERIUM
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed Patient Informed Consent Form for participation in the study; 2. Men and women 18 years and older; 3. Diagnosis of cystic fibrosis, defined as the presence of disease symptoms and a positive sweat test and / or detection of 2 mutations of the MVTR gene during genotyping; 4. FEV1 ≥40% and ≤100% of the proper value; 5. The ability to understand the protocol requirements, to give written consent to participate in the study (including the use and transfer of information about the patient's health status related to the study).
Exclusion criteria
1. Hypersensitivity to any of used study drug, to their components, as well as a history of significant allergic reactions; 2. Acute respiratory infection or exacerbation of chronic pulmonary disease within 4 weeks prior to screening and without corticosteroid or antibiotic therapy; 3. Concomitant diseases and conditions with potential impact the patients safety, including: * Severe renal impairment (serum creatinine more than 1.5 times higher than the upper limit of normal); * Severe liver impairment (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) blood serum activity is 2.5 times or more higher than the upper limit of the laboratory norm); 4. A history of lung transplantation or planned transplantation during this study; 5. The presence of antibodies to HIV, active viral hepatitis B and / or C and / or cirrhosis in the history or detected on Screening; 6. Pregnancy and lactation; 7. Refusal of patients with preserved reproductive potential to use adequate contraception throughout the study and within 30 days after the end of the study; 8. Patients who underwent a blood or blood components transfusion within 10 days prior to screening; 9. Drug or alcohol abuse at the time of Screening or in the past; 10. Patient's participation in any other clinical trials and / or administration of an experimental drug within 30 days prior to the Screening Visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in forced expiratory volume in the first second of a forced expiratory maneuver (FEV1) compared to baseline | FEV1 - forced expiratory volume in the first second of a forced expiratory maneuver by standard spirometry | Week 24 ± 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in forced lung capacity (FVC) compared to baseline | Week 24 ± 1 | FVC - forced lung capacity by standard spirometry |
| The number of exacerbations of chronic pulmonary disease | Week 24 ± 1 | Clinical symptoms of chronic pulmonary disease exacerbation required antibiotic therapy in CF patients, include the presence of at least 4 of 12 possible signs or symptoms 1. A change in color or amount of sputum; 2. The appearance or intensification of hemoptysis; 3. Strengthening cough; 4. Increased shortness of breath; 5. Increased malaise, fatigue or lethargy; 6. Temperature above 38 ° C; 7. Anorexia or weight loss; 8. Sinuses pain or soreness; 9. Changes in the nature of sinuses mucus; 10. Changes in chest physical examination; 11. Pulmonary function decrease at list 10% or more; 12. Radiographic changes. |
| The number of days before the chronic pulmonary disease exacerbation development | Week 24 ± 1 | — |
| Change in body weight compared to baseline | Week 24 ± 1 | — |
| Change in the average score for the Symptoms, Activity, Influence subscales, as well as the average total score of the St. George's Respiratory Questionnaire (SGRQ), version 2.2 | Week 24 ± 1 | St. George's Respiratory Questionnaire (SGRQ), a questionnaire for patients with respiratory diseases is designed to assess the chronic obstructive pulmonary disease patients quality of life. The questionnaire consists of 76 questions, which are grouped in 3 parts: * The first part - symptoms - measures the degree of anxiety caused by respiratory symptoms. * The second part - activity - measures the limitation of mobility and physical activity. * The third part - the influence - evaluates the existing psychosocial consequences of bronchial obstruction. |
Countries
Russia
Outcome results
None listed